Filing Flows › C4 Therapeutics (CCCC) › Guidance & outlook
C4 Therapeutics (CCCC) guidance and outlook
C4 Therapeutics' 10-Q filed Nov 5, 2026 makes 21 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients’ lives.
- Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small-molecule protein degraders that are highly active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins.
- Our most advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3.
- Enrollment in the trial is ongoing and we expect to report data from all cohorts in mid-2027.
- In addition, we plan to initiate an additional Phase 1b trial in the first half of 2027 that will evaluate cemsidomide across two treatment arms, (1) cemsidomide, dexamethasone, and daratumumab, an anti-CD38 antibody, or (2) cemsidomide, dexamethasone, and carfilzomib, a proteasome inhibitor.
- Based on the evolving treatment landscape for EGFR mutated NSCLC, capital priorities, and available clinical data to date, we will not advance CFT8919 into the next phase of clinical development outside of Greater China at this time.
- A key part of our strategy is selecting targets where there is a strong degrader rationale over other therapeutic modalities.
- To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future.
- We recognize revenue over the expected performance period under each agreement.
- We expect that our revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future.
- We expect that our research and development expenses will increase substantially in connection with our planned preclinical and clinical development activities.
- We expect that our general and administrative expenses will potentially increase in the future to support increased research and development activities.
C4 Therapeutics' latest quarter
C4 Therapeutics, Q3 2026: revenue $8.5M (-25% year over year), operating margin -290.5%, net loss $21.8M, operating cash flow −$26.0M. The chart follows the revenue to costs, profit and cash.
Questions
What does C4 Therapeutics expect?
We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients’ lives. Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small-molecule protein degraders that are highly active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Our most advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.